4 completed, 1 unknown, 1 withdrawn. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Liu Tian: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Upadacitinib for Refractory Takayasu Arteritis Takayasu Arteritis | Completed | Liu Tian | 12 | 2024-03-19 | 2026-03-30 | |
| Upadacitinib for Refractory Behcet's Syndrome Upadacitinib 15 MG - Behcet Syndrome | Phase 2 | Completed | Liu Tian | 27 | 2024-01-25 | 2025-12-02 |
| Baricitinib for Refractory Takayasu Arteritis Baricitinib 4 MG - Takayasu Arteritis | Phase 2 | Completed | Liu Tian | 10 | 2023-04-03 | 2024-10-29 |
| Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus Telitacicept, Interleukin-2 - Systemic Lupus Erythematosus | Phase 3 | Unknown | Liu Tian | 60 | 2023-02-07 | 2024-04-03 |
Behcet Syndrome (3) · Takayasu Arteritis (2) · Lupus Erythematosus, Systemic (1) · Myelodysplastic Syndromes (1)
Interleukin-2 (1) · RC-18 (1) · Ustekinumab (1) · baricitinib (1) · ivarmacitinib (1) · telitacicept (1) · upadacitinib (1)
China (6)
Zhanguo Li (1)